molsidomine has been researched along with Angina Pectoris, Stable in 3 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbato, E | 2 |
| Herman, A | 2 |
| Benit, E | 2 |
| Janssens, L | 2 |
| Lalmand, J | 2 |
| Hoffer, E | 2 |
| Chenu, P | 2 |
| Guédès, A | 2 |
| Missault, L | 2 |
| Pirenne, B | 2 |
| Cardinal, F | 2 |
| Vercauteren, S | 2 |
| Wijns, W | 2 |
| Messin, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind Parallel Placebo-controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients With Stable Angina Pectoris Undergoing a Percutaneous Coronary Intervention[NCT01363661] | Phase 4 | 165 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The results are expressed mean relative change (%) between month 12 and baseline. A positive result means improvement in the score of the EndoPAT between baseline and month 12. It could be considered as a surrogate of a decrease of the endothelial dysfunction. A negative percentage means the inverse. The are no fixed limits to the scale. The minimum observed was -275% and the maximum observed was +4200%. (NCT01363661)
Timeframe: 12 months
| Intervention | Relative change versus baseline (%) (Mean) |
|---|---|
| Molsidomine | 330.60 |
| Placebo | 164.08 |
The results are expressed mean relative change (%) between month 6 and baseline. A positive result means improvement in the score of the EndoPAT between baseline and month 6. It could be considered as a surrogate of a decrease of the endothelial dysfunction. A negative percentage means the inverse. The are no fixed limits to the scale. The minimum observed was -200% and the maximum observed was +6100%. (NCT01363661)
Timeframe: Month 6
| Intervention | Relative change versus baseline (%) (Mean) |
|---|---|
| Molsidomine | 361.98 |
| Placebo | 326.26 |
Sum of the events collected during 12 months. (NCT01363661)
Timeframe: Month 12
| Intervention | Number of events (Number) |
|---|---|
| Molsidomine | 3 |
| Placebo | 1 |
(NCT01363661)
Timeframe: Month 12
| Intervention | Relative change versus baseline (%) (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Endothelial microparticles | Platelet microparticles | Leukocyte microparticles | sICAM-1 | IL-8 | hs-CRP | MOX-LDL | MPO antigen | MPO activity | MPO activity/antigen ratio | |
| Molsidomine | -40 | 0.5 | -39 | -6 | 13 | -50 | 11 | -1 | -43 | -42 |
| Placebo | -40 | -23 | -37 | 6 | -25 | -35 | 41 | -32 | 8 | 7 |
The results are expressed mean relative change (%) between month 6 or month 12, and baseline. A positive result means improvement in the augmentation index between baseline and month 6 or month 12. It could be considered as a surrogate of a decrease of the arterial stiffness. A negative percentage means the inverse. The are no fixed limits to the scale. At month 6,the minimum observed was -139% and the maximum observed was +1600%.At month 12, the minimum observed was -524% and the maximum observed was +1600%. (NCT01363661)
Timeframe: Month 6 and Month 12
| Intervention | Relative change versus baseline (%) (Mean) | |
|---|---|---|
| Month 6 | Month 12 | |
| Molsidomine | 218.07 | 98.57 |
| Placebo | 96.35 | 95.13 |
Sum of the events collected during 12 months. (NCT01363661)
Timeframe: Month 12
| Intervention | Number of events (Number) | |
|---|---|---|
| Non-serious AE | SAE | |
| Molsidomine | 57 | 7 |
| Placebo | 79 | 12 |
2 trials available for molsidomine and Angina Pectoris, Stable
| Article | Year |
|---|---|
Double-blind parallel placebo-controlled study to evaluate the effect of molsidomine on the endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: the MEDCOR Trial.
Topics: Angina, Stable; Belgium; Clinical Protocols; Coronary Vessels; Double-Blind Method; Drug Therapy, Co | 2014 |
Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: results of the MEDCOR trial.
Topics: Aged; Angina, Stable; Belgium; Biomarkers; Combined Modality Therapy; Coronary Artery Disease; Doubl | 2015 |
1 other study available for molsidomine and Angina Pectoris, Stable
| Article | Year |
|---|---|
Comparative short-term effect of once-daily molsidomine on chronic angina in general practitioners' versus cardiologists' coronary patient populations.
Topics: Aged; Aged, 80 and over; Angina, Stable; Cardiology; Drug Administration Schedule; Female; General P | 2014 |